Posts by Liron Bar-Peled, PhD
-
"DrugMap" Expected to Accelerate Cancer Drug Discovery
Liron Bar-Peled, PhD, Michael Lawrence, PhD, and colleagues have developed "DrugMap," an atlas of cysteine ligandability compiled across 416 cancer cell lines that lays the groundwork for precision anti-cancer drugs to be systematically developed for additional classes of oncogenic drivers.
-
Novel Technology Finds New Targets Among So-Called 'Undruggable' Cancer Targets
Massachusetts General Hospital researchers have developed a novel technology using chemical proteomics to identify new drug targets among "undruggable" cancer targets.
Biography
Liron Bar-Peled, PhD, is an investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of medicine at Harvard Medical School.
Mass General Brigham Cancer Institute
Mass General Brigham Cancer Institute unites leading experts and resources across our academic medical centers, making it one of the nation’s top providers of cancer care.